Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7064400 | 0.88 | FKBP1A (0.50) | FKBP1ASMN1; SMN2NPC1RAB9APREP | |
| SCHEMBL7064334 | 0.86 | FKBP1A (0.48) | FKBP1ASMN1; SMN2NPC1RAB9APREP | |
| SCHEMBL5785042 | 0.84 | CACNA1A (0.57) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL10579873 | 0.84 | FKBP1A (0.54) | FKBP1ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL7066507 | 0.81 | FKBP1A (0.47) | FKBP1ASMN1; SMN2NPC1RAB9APREP | |
| SCHEMBL2770710 | 0.81 | KMT2A (0.48) | CYP2C19AGTR2 | |
| SCHEMBL7062463 | 0.80 | CCR1 (0.46) | FKBP1A | |
| SCHEMBL7066355 | 0.80 | FKBP1A (0.47) | FKBP1APREP | |
| SCHEMBL5685743 | 0.79 | ALDH1A1 (0.47) | AGTR2 | |
| SCHEMBL5685826 | 0.79 | ALDH1A1 (0.47) | AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56032454-A | — | — | None | — | — | JP | disclosed |
| EP-1193253-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACIDS | KANEKA CORP (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-1927588-A2 | Process for producing optically active azetidine-2-carboxylic acids | KANEKA CORPORATION (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-7262308-B2 | Process for producing optically active azetidine-2-carboxylic acids | KANEKA CORPORATION (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20050043547-A1 | Process for producing optically active azetidine-2-carboxylic acids | HONDA TATSUYA (JP) | 2005-02-24 | — | — | US | disclosed |
| US-6838567-B1 | Process for producing optically active azetidine-2-carboxylic acids | KANEKA CORPORATION (JP) | 2005-01-04 | — | — | US | disclosed |
| US-20040171849-A1 | Process for producing optically active azetidine-2-carboxylic acid | KANEKA CORPORATION (JP) | 2004-09-02 | — | — | US | disclosed |
| EP-1415985-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE AZETIDINE-2-CARBOXYLIC ACID | KANEKA CORPORATION (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-0992491-B1 | PROCESSES FOR PRODUCING AZETIDINE-2-CARBOXYLIC ACID AND INTERMEDIATES THEREOF | KANEKA CORP (JP) | 2003-03-05 | — | — | EP | disclosed |
| EP-0950057-B1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LAB (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6150535-A | Processes for producing azetidine-2-carboxylic acid and intermediates thereof | KANEKA CORPORATION (JP) | 2000-11-21 | — | — | US | disclosed |
| EP-1047690-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2000-11-02 | — | — | EP | disclosed |
| US-6133253-A | NEURONAL CELL DEATH PREVENTORS AND ANTI-INFLAMMATORIES | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0992491-A1 | PROCESSES FOR PRODUCING AZETIDINE-2-CARBOXYLIC ACID AND INTERMEDIATES THEREOF | KANEKA CORPORATION (JP) | 2000-04-12 | — | — | EP | disclosed |
| EP-0950057-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | Abbott Laboratories (US) | 1999-10-20 | — | — | EP | disclosed |
| WO-1999032480-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998025920-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LABORATORIES (US) | 1998-06-18 | — | — | WO | disclosed |
| US-4349547-A | Suppressing obesity and over-secretion of insulin with 2-(α-hydroxy-m-trifluoromethylbenzyl)azetidine | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1982-09-14 | — | — | US | disclosed |
| EP-0025880-A1 | Azetidine derivative, its production, the derivative for use as an anti-obesity agent | Takeda Chemical Industries, Ltd. (JP) | 1981-04-01 | — | — | EP | disclosed |
| JP-S5632454-A | AZETIDINE DERIVATIVE | TAKEDA CHEM IND LTD | 1981-04-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171849-A1 | Process for producing optically active azetidine-2-carboxylic acid | HBB, ADCY2, ADCY9 | FKBP1A 2054/4885SMN1; SMN2 1956/4885NPC1 2874/4885 |
| US-20050043547-A1 | Process for producing optically active azetidine-2-carboxylic acids | AZI2, ALAD, HBB | FKBP1A 1857/4885SMN1; SMN2 2424/4885NPC1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.